Cargando…

Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco

BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically...

Descripción completa

Detalles Bibliográficos
Autores principales: Haban, Houda, Benchekroun, Soumia, Sadeq, Mina, Benjouad, Abdelaziz, Amzazi, Said, Oumzil, Hicham, Elharti, Elmir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622525/
https://www.ncbi.nlm.nih.gov/pubmed/28962610
http://dx.doi.org/10.1186/s12889-017-4776-8
_version_ 1783267928013012992
author Haban, Houda
Benchekroun, Soumia
Sadeq, Mina
Benjouad, Abdelaziz
Amzazi, Said
Oumzil, Hicham
Elharti, Elmir
author_facet Haban, Houda
Benchekroun, Soumia
Sadeq, Mina
Benjouad, Abdelaziz
Amzazi, Said
Oumzil, Hicham
Elharti, Elmir
author_sort Haban, Houda
collection PubMed
description BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country. METHODS: Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups. RESULTS: The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. CONCLUSION: In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children.
format Online
Article
Text
id pubmed-5622525
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56225252017-10-11 Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco Haban, Houda Benchekroun, Soumia Sadeq, Mina Benjouad, Abdelaziz Amzazi, Said Oumzil, Hicham Elharti, Elmir BMC Public Health Research Article BACKGROUND: Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country. METHODS: Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups. RESULTS: The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response. CONCLUSION: In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children. BioMed Central 2017-09-29 /pmc/articles/PMC5622525/ /pubmed/28962610 http://dx.doi.org/10.1186/s12889-017-4776-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Haban, Houda
Benchekroun, Soumia
Sadeq, Mina
Benjouad, Abdelaziz
Amzazi, Said
Oumzil, Hicham
Elharti, Elmir
Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title_full Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title_fullStr Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title_full_unstemmed Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title_short Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco
title_sort assessment of the hbv vaccine response in a group of hiv-infected children in morocco
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622525/
https://www.ncbi.nlm.nih.gov/pubmed/28962610
http://dx.doi.org/10.1186/s12889-017-4776-8
work_keys_str_mv AT habanhouda assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT benchekrounsoumia assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT sadeqmina assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT benjouadabdelaziz assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT amzazisaid assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT oumzilhicham assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco
AT elhartielmir assessmentofthehbvvaccineresponseinagroupofhivinfectedchildreninmorocco